[{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara to present at Transplantation & Cellular Therapy 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the ECCMID Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin In Patients Undergoing Allogeneic Blood And Marrow Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Rezafungin in EU for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics to Present New Data for Rezafungin AND Influenza AVCS at the 21 St ICHS Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics New Data for Rezafungin at the (ISHAM) Asia Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"$568.0 million","upfrontCash":"$30.0 million","newsHeadline":"Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"$30.0 million","newsHeadline":"Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of Rezzayo\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and\/or Invasive Candidiasis at ECCMID 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and\/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"$568.0 million","upfrontCash":"$39.0 million","newsHeadline":"Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Announces Acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis to the UK Medicines and Healthcare Products Regulatory Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO\u2122 (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Provides Update on REZZAYO\u2122 (rezafungin for injection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO\u2122 (rezafungin for injection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma and Cidara Therapeutics Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma Announces European Approval of REZZAYO\u00ae (rezafungin) for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces European Approval of REZZAYO\u00ae (rezafungin) for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Announces Authorisation Of REZZAYO\u00ae (Rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency For the Treatment of Invasive Candidiasis in Adults1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Rezafungin
The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
Rezzayo (rezafungin) is a novel once-weekly echinocandin, a 1,3-beta-glucan synthase inhibitor. It is approved for the treatment of invasive candidiasis.
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin antifungal approved by USFDA. It is now approved by MHRA for the treatment of invasive candidiasis in adults.
Rezzayo (rezafungin) is an echinocandin antifungal that helps to inhibit the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls. It recently got EU approval for the treatment of invasive candidiasis in adults.
Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age
or older who have limited or no alternative options for the treatment of
candidemia and invasive candidiasis.
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin and 1,3-beta-glucan synthase inhibitor. It is approved for the treatment for Invasive Candidiasis in adults.
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being used for the treatment and prevention of adult patients with candidemia and invasive candidiasis.
Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Under the agreement, Melinta acquired exclusive rights to commercialize Rezzayo (rezafungin) in the U.S. from Cidara. Cidara recently received FDA approval for REZZAYO™, a novel, once-weekly echinocandin antifungal approved for candidemia and invasive candidiasis.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
